The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Inflammation and the Degenerative Diseases of Aging
Abstract
A bstract: Chronic inflammation is associated with a broad spectrum of neurodegenerative diseases of aging. Included are such disorders as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis, the Parkinson‐dementia complex of Guam, all of the tauopathies, and age‐related macular degeneration. Also included are such peripheral conditions as osteoarthritis, rheumatoid arthritis, atherosclerosis, and myocardial infarction. Inflammation is a two‐edged sword. In acute situations, or at low levels, it deals with the abnormality and promotes healing. When chronically sustained at high levels, it can seriously damage viable host tissue. We describe this latter phenomenon as autotoxicity to distinguish it from autoimmunity. The latter involves a lymphocyte‐directed attack against self proteins. Autotoxicity, on the other hand, is determined by the concentration and degree of activation of tissue‐based monocytic phagocytes. Microglial cells are the brain representatives of the monocyte phagocytic system. Biochemically, the intensity of their activation is related to a spectrum of inflammatory mediators generated by a variety of local cells. The known spectrum includes, but is not limited to, prostaglandins, pentraxins, complement components, anaphylotoxins, cytokines, chemokines, proteases, protease inhibitors, adhesion molecules, and free radicals. This spectrum offers a huge variety of targets for new anti‐inflammatory agents. It has been suggested, largely on the basis of transgenic mouse models, that stimulating inflammation rather than inhibiting it can be beneficial in such diseases as AD. If this were the case, administration of NSAIDs, or other anti‐inflammatory drugs, would be expected to exacerbate conditions such as AD, PD, and atherosclerosis. However, epidemiological evidence overwhelmingly demonstrates that the reverse is true. This indicates that, at least in these diseases, the inflammation is harmful. So far, advantage has not been taken of opportunities indicated by these epidemiological studies to treat AD and PD with appropriate anti‐inflammatory agents. Based on this evidence, classical NSAIDs are the most logical choice. Dosage, though, must be sufficient to combat the inflammation. Analysis of mRNA levels of inflammatory mediators indicates that the intensity of inflammation is considerably higher in AD hippocampus and in PD substantia nigra than in osteoarthritic joints. Thus, full therapeutic doses of NSAIDs, or combinations of anti‐inflammatory agents, are needed to achieve the suggested neurological benefits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
The many faces of macrophage activation
Mosser, D. M. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0602325 · Cited by 1,902
McGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367
Self-citationMCGEER, P., & MCGEER, E. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(95)00011-9 · Cited by 1,287
Self-citationNonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196
Risk of Alzheimer's disease and duration of NSAID use
Stewart, W. F., Kawas, C., Corrada, M., & Metter, E. J. (1997) · Neurology · doi:10.1212/wnl.48.3.626 · Cited by 1,132
Banati, R. B., Gehrmann, J., Schubert, P., & Kreutzberg, G. W. (1993) · Glia · doi:10.1002/glia.440070117 · Cited by 1,029
Clinical trial of indomethacin in Alzheimer's disease
Rogers, J., Kirby, L. C., Hempelman, S. R., Berry, D. L., McGeer, P. L., Kaszniak, A. W., Zalinski, J., Cofield, M., Mansukhani, L., Willson, P., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1609 · Cited by 999
Self-citationComplement activation by beta-amyloid in Alzheimer disease.
Rogers, J., Cooper, N. R., Webster, S., Schultz, J., McGeer, P. L., Styren, S. D., Civin, W. H., Brachova, L., Bradt, B., & Ward, P. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.21.10016 · Cited by 817
Self-citation
Cited by
Neuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984
The role of inflammation in CNS injury and disease
Lucas, S., Rothwell, N. J., & Gibson, R. M. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706400 · Cited by 1,272
“The complement cascade is activated, and mRNAs for complement proteins are upregulated in PD (and AD) to a greater extent than in peripheral inflammatory diseases such as rheumatoid arthritis (reviewed by McGeer & McGeer, 2004).”
BackgroundForsyth, C. B., Shannon, K. M., Kordower, J. H., Voigt, R. M., Shaikh, M., Jaglin, J. A., Estes, J. D., Dodiya, H. B., & Keshavarzian, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028032 · Cited by 974
Xu, M., Tchkonia, T., Ding, H., Ogrodnik, M., Lubbers, E. R., Pirtskhalava, T., White, T. A., Johnson, K. O., Stout, M. B., Mezera, V., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1515386112 · Cited by 915
The amyloid hypothesis for Alzheimer’s disease: A critical reappraisal
Hardy, J. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06181.x · Cited by 814
Age-related macular degeneration
de Jong, P. T. V. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmra062326 · Cited by 787
Para-Inflammation in the Aging Retina
Xu, H., Chen, M., & Forrester, J. V. (2009) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2009.06.001 · Cited by 659
Neuroinflammation in Parkinson's disease
Hirsch, E. C., Vyas, S., & Hunot, S. (2012) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(11)70065-7 · Cited by 657
Tansey, M. G., McCoy, M. K., & Frank-Cannon, T. C. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.07.004 · Cited by 583
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
Role of the Toll-Like Receptor 4 in Neuroinflammation in Alzheimer’s Disease
Walter, S., Letiembre, M., Liu, Y., Heine, H., Penke, B., Hao, W., Bode, B., Manietta, N., Walter, J., Schulz-Schüffer, W., et al. (2007) · Cellular Physiology and Biochemistry · doi:10.1159/000110455 · Cited by 543
NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies
McGeer, P. L., & McGeer, E. G. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.03.013 · Cited by 498
Self-citationThe Role of Inflammation in the Pathogenesis of Age-related Macular Degeneration
Donoso, L. A., Kim, D., Frost, A., Callahan, A., & Hageman, G. (2006) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2005.12.001 · Cited by 483
Synuclein activates microglia in a model of Parkinson's disease
Su, X., Maguire-Zeiss, K. A., Giuliano, R., Prifti, L., Venkatesh, K., & Federoff, H. J. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.04.006 · Cited by 474
Signaling pathways in Parkinson’s disease: molecular mechanisms and therapeutic interventions
Dong-Chen, X., Yong, C., Yang, X., Chen-Yu, S., & Li-Hua, P. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01353-3 · Cited by 469
Broza, Y. Y., Zhou, X., Yuan, M., Qu, D., Zheng, Y., Vishinkin, R., Khatib, M., Wu, W., & Haick, H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00437 · Cited by 461
Agrawal, A., Agrawal, S., Cao, J.-N., Su, H., Osann, K., & Gupta, S. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.11.6912 · Cited by 435
Grammas, P. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-26 · Cited by 432
“markers of inflammation in the AD brain [64-71].”
BackgroundMhyre, T. R., Boyd, J. T., Hamill, R. W., & Maguire-Zeiss, K. A. (2012) · Subcellular Biochemistry · doi:10.1007/978-94-007-5416-4_16 · Cited by 423
Parainflammation, Chronic Inflammation and Age-Related Macular Degeneration
Chen, M., & Xu, H. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.3ri0615-239r · Cited by 381
Inflammasomes in neuroinflammation and changes in brain function: a focused review
Singhal, G., Jaehne, E. J., Corrigan, F., Toben, C., & Baune, B. T. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00315 · Cited by 365
Molecular mechanisms of aging-associated inflammation
Sarkar, D., & Fisher, P. B. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.04.009 · Cited by 359
The Biology of Aging and Frailty
Fedarko, N. S. (2011) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2010.08.006 · Cited by 341
Role of inflammation in neurodegenerative diseases
Minghetti, L. (2005) · Current Opinion in Neurology · doi:10.1097/01.wco.0000169752.54191.97 · Cited by 335
Features of Microglia and Neuroinflammation Relevant to Environmental Exposure and Neurotoxicity
Kraft, A. D., & Harry, G. J. (2011) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph8072980 · Cited by 326
Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease
Collins, L. M., Toulouse, A., Connor, T. J., & Nolan, Y. M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.01.028 · Cited by 306
Daniele, S. G., Béraud, D., Davenport, C., Cheng, K., Yin, H., & Maguire-Zeiss, K. A. (2015) · Science Signaling · doi:10.1126/scisignal.2005965 · Cited by 303
Phillip, J. M., Aifuwa, I., Walston, J., & Wirtz, D. (2015) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071114-040829 · Cited by 301
Anti-inflammatory role of microglial alpha7 nAChRs and its role in neuroprotection
Egea, J., Buendia, I., Parada, E., Navarro, E., León, R., & Lopez, M. G. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.07.032 · Cited by 298
The influence of microglia on the pathogenesis of Parkinson's disease
Long-Smith, C. M., Sullivan, A. M., & Nolan, Y. M. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.08.001 · Cited by 296
Age-associated chronic diseases require age-old medicine: Role of chronic inflammation
Prasad, S., Sung, B., & Aggarwal, B. B. (2012) · Preventive Medicine · doi:10.1016/j.ypmed.2011.11.011 · Cited by 290
Lagoumtzi, S. M., & Chondrogianni, N. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.05.003 · Cited by 279
Microglia, Amyloid, and Glucose Metabolism in Parkinson’s Disease with and without Dementia
Edison, P., Ahmed, I., Fan, Z., Hinz, R., Gelosa, G., Ray Chaudhuri, K., Walker, Z., Turkheimer, F. E., & Brooks, D. J. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.255 · Cited by 274
Zlokovic, B. V., Deane, R., Sagare, A. P., Bell, R. D., & Winkler, E. A. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07002.x · Cited by 261
An elt-3/elt-5/elt-6 GATA transcription circuit guides aging in C. elegans
Budovskaya, Y. V., Wu, K., Southworth, L. K., Jiang, M., Tedesco, P., Johnson, T. E., & Kim, S. K. (2008) · Cell · doi:10.1016/j.cell.2008.05.044 · Cited by 253
Vukic, V., Callaghan, D., Walker, D., Lue, L.-F., Liu, Q. Y., Couraud, P.-O., Romero, I. A., Weksler, B., Stanimirovic, D. B., & Zhang, W. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.12.007 · Cited by 232
“Aβ-stimulated neuroinflammation contributes to neurodegeneration in Alzheimer's disease (McGeer and McGeer 2001, 2004; Craft et al., 2006).”
BackgroundInfluentialThe beneficial effects of fruit polyphenols on brain aging
Lau, F. C., Shukitt-Hale, B., & Joseph, J. A. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.08.007 · Cited by 217
Stress increases vulnerability to inflammation in the rat prefrontal cortex
de Pablos, R. M., Villarán, R. F., Argüelles, S., Herrera, A. J., Venero, J. L., Ayala, A., Cano, J., & Machado, A. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0802-06.2006 · Cited by 215
Intermittent fasting attenuates lipopolysaccharide-induced neuroinflammation and memory impairment.
Vasconcelos, A. R., Yshii, L. M., Viel, T. A., Buck, H. S., Mattson, M. P., Scavone, C., & Kawamoto, E. M. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-85 · Cited by 210
Antidepressants inhibit interferon-γ-induced microglial production of IL-6 and nitric oxide
Hashioka, S., Klegeris, A., Monji, A., Kato, T., Sawada, M., McGeer, P. L., & Kanba, S. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.03.022 · Cited by 198
Self-citationCyclooxygenase-2 in synaptic signaling
Yang, H., & Chen, C. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208784480144 · Cited by 195
Tau depletion prevents progressive blood-brain barrier damage in a mouse model of tauopathy
Blair, L. J., Frauen, H. D., Zhang, B., Nordhues, B. A., Bijan, S., Lin, Y.-C., Zamudio, F., Hernandez, L. D., Sabbagh, J. J., Selenica, M.-L. B., et al. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0186-2 · Cited by 193
Valles, S. L., Dolz-Gaiton, P., Gambini, J., Borras, C., LLoret, A., Pallardo, F. V., & Viña, J. (2010) · Brain Research · doi:10.1016/j.brainres.2009.11.044 · Cited by 186
Inflammation, the complement system and the diseases of aging
McGeer, E. G., Klegeris, A., & McGeer, P. L. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.08.008 · Cited by 170
Self-citationStress is critical for LPS-induced activation of microglia and damage in the rat hippocampus
Espinosa-Oliva, A. M., de Pablos, R. M., Villarán, R. F., Argüelles, S., Venero, J. L., Machado, A., & Cano, J. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.01.012 · Cited by 151
Mutant α-Synuclein Overexpression Mediates Early Proinflammatory Activity
Su, X., Federoff, H. J., & Maguire-Zeiss, K. A. (2009) · Neurotoxicity Research · doi:10.1007/s12640-009-9053-x · Cited by 145
Transcriptional Control of Monocyte Gene Expression in Post-Traumatic Stress Disorder
O’Donovan, A., Sun, B., Cole, S., Rempel, H., Lenoci, M., Pulliam, L., & Neylan, T. (2011) · Disease Markers · doi:10.1155/2011/560572 · Cited by 141
Lavisse, S., Goutal, S., Wimberley, C., Tonietto, M., Bottlaender, M., Gervais, P., Kuhnast, B., Peyronneau, M.-A., Barret, O., Lagarde, J., et al. (2021) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.11.011 · Cited by 127
Neuroinflammation: a potential therapeutic target
Craft, J. M., Watterson, D. M., & Van Eldik, L. J. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.5.887 · Cited by 116
Johansson, J. U., Pradhan, S., Lokteva, L. A., Woodling, N. S., Ko, N., Brown, H. D., Wang, Q., Loh, C., Cekanaviciute, E., Buckwalter, M., et al. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.2203-13.2013 · Cited by 96
Palasz, E., Niewiadomski, W., Gasiorowska, A., Wysocka, A., Stepniewska, A., & Niewiadomska, G. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01143 · Cited by 95
Microglia in Alzheimer's Disease: It's All About Context
Weitz, T. M., & Town, T. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/314185 · Cited by 95
“In addition to the well-accepted notion that microglia are closely associated with senile plaques in AD, it has also been shown that numerous inflammatory mediators are upregulated in affected areas of the AD brain [17].”
BackgroundZhao, M., Bai, Y., Xie, W., Shi, X., Li, F., Yang, F., Sun, Y., Huang, L., & Li, X. (2015) · PLOS ONE · doi:10.1371/journal.pone.0125150 · Cited by 88
A paradox of immunodeficiency and inflammation in human aging: lessons learned from apoptosis
Gupta, S., Agrawal, A., Agrawal, S., Su, H., & Gollapudi, S. (2006) · Immunity & Ageing · doi:10.1186/1742-4933-3-5 · Cited by 77
miRNAs as potential therapeutic targets for age-related macular degeneration
Wang, S., Koster, K. M., He, Y., & Zhou, Q. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.11.176 · Cited by 67
Vulnerability of mesostriatal dopaminergic neurons in Parkinson’s disease
González-Hernández, T. (2010) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2010.00140 · Cited by 65
Mapping neuroinflammation in frontotemporal dementia with molecular PET imaging
Zhang, J. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0236-5 · Cited by 62
Primiani, C. T., Ryan, V. H., Rao, J. S., Cam, M. C., Ahn, K., Modi, H. R., & Rapoport, S. I. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110972 · Cited by 56
PKR, the double stranded RNA‐dependent protein kinase as a critical target in Alzheimer's disease
Morel, M., Couturier, J., Lafay‐Chebassier, C., Paccalin, M., & Page, G. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00849.x · Cited by 47
Peroxisome proliferator-activated receptor and age-related macular degeneration
Herzlich, A. A., Tuo, J., & Chan, C.-C. (2008) · PPAR Research · doi:10.1155/2008/389507 · Cited by 43
Inflammation in the Alzheimer's disease cascade: culprit or innocent bystander?
Tan, Z. S., & Seshadri, S. (2010) · Alzheimer's Research & Therapy · doi:10.1186/alzrt29 · Cited by 39
Tsap, M. I., Yatsenko, A. S., Hegermann, J., Beckmann, B., Tsikas, D., & Shcherbata, H. R. (2024) · eLife · doi:10.7554/elife.98020 · Cited by 8
Kim, H.-J., Narayanankutty, A., Sasidharan, A., Job, J. T., Kim, Y. O., Na, S. W., Rajagopal, R., Alfarhan, A., & Al-Munqedhi, B. (2022) · Journal of King Saud University - Science · doi:10.1016/j.jksus.2021.101715 · Cited by 3
Metadata
- Authors
- McGEER, P. L., & McGEER, E. G.
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 2004-12
- Volume
- 1035
- Issue
- 1
- Pages
- 104-116
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- OpenAlex
- W2050206306
- Cited by
- 518
- References
- 78
- FWCI
- 18.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.